Research programme: Escherichia coli vaccine - Syntiron
Latest Information Update: 28 Feb 2022
Price :
$50 *
At a glance
- Originator Syntiron
- Class Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Escherichia coli infections
Highest Development Phases
- No development reported Escherichia coli infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Escherichia-coli-infections in USA
- 23 Jan 2018 Escherichia coli vaccine - Syntiron is available for licensing as of 23 Jan 2018. http://syntiron.com/about-us/
- 23 Jan 2018 Preclinical trials in Escherichia coli infections in USA (unspecified route) (Syntiron pipeline, January 2018)